Document is current
Any future updates will be listed below
-
Authors
Houser, Madelyn C.
Caudle, W. Michael
Chang, Jianjun
Kannarkat, George T.
Yang, Yuan
Kelly, Sean D.
Oliver, Danielle
Joers, Valerie
Shannon, Kathleen M.
Keshavarzian, Ali
Tansey, Malú Gámez http://orcid.org/0000-0002-1719-4708
-
Funding
Funding for this research was provided by:
HHS-NIH (UL1TR002378)
National Institute of Neurological Disorders and Stroke (5R01NS092122)
National Institute on Aging (1RF1AG057247)
National Science Foundation (DGE-1444932)
National Parkinson Foundation (Research Center of Excellence Gut-Brain)
- License Information
-
More Information
Article History
Received: 8 June 2021
Accepted: 3 August 2021
First Online: 19 August 2021
Declarations
:
: Aspects of this study involving humans were conducted in accordance with the principles of the Declaration of Helsinki and were approved by the RUMC Institutional Review Board (IRB) and registered at Clinicaltrials.gov (NCT01155492) or by the Emory University IRB. All subjects provided written informed consent prior to inclusion in the study. Aspects of this study involving animals were conducted in accordance with National Institutes of Health animal care and use policies and in consultation with veterinary staff and were approved by the Emory University Institutional Animal Care and Use Committee.
: Not applicable.
: MGT is an ex-employee of Xencor Inc. and co-inventor on the dominant-negative TNF patent; an advisor to the Alzheimer’s Association, Michael J. Fox Foundation for Parkinson’s Research, W. Garfield Weston Foundation, Quebec Parkinson’s Network, and World Parkinson’s Coalition; and a paid consultant for INmune Bio, Prevail Therapeutics, Regenex, Cerebral Therapeutics, and Longevity Biotech. KMS receives grant funding from Eli Lilly and Sun Pharma and is an unpaid consultant for Axial Biotherapeutics.
